These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1360097)

  • 1. Surfactant for babies.
    Lancet; 1992 Dec; 340(8832):1387. PubMed ID: 1360097
    [No Abstract]   [Full Text] [Related]  

  • 2. OSIRIS trial.
    Morley C
    Lancet; 1993 Jan; 341(8838):172-3; author reply 173-4. PubMed ID: 8093764
    [No Abstract]   [Full Text] [Related]  

  • 3. OSIRIS trial.
    Gore SM
    Lancet; 1993 Jan; 341(8838):172; author reply 173-4. PubMed ID: 8093762
    [No Abstract]   [Full Text] [Related]  

  • 4. OSIRIS trial.
    Robertson B; Speer CP
    Lancet; 1993 Jan; 341(8838):172; author reply 173-4. PubMed ID: 8093763
    [No Abstract]   [Full Text] [Related]  

  • 5. Criteria for use of colfosceril (Exosurf) in neonates.
    Bhatt-Mehta V; Schumacher RE
    Clin Pharm; 1992 Apr; 11(4):355-7. PubMed ID: 1563234
    [No Abstract]   [Full Text] [Related]  

  • 6. Early or selective surfactant (colfosceril palmitate, Exosurf) for intubated babies at 26 to 29 weeks gestation. A European double-blind trial with sequential analysis. European Exosurf Study Group.
    Online J Curr Clin Trials; 1992 Nov; Doc No 28():[3886 words; 47 paragraphs]. PubMed ID: 1343614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early versus delayed neonatal administration of a synthetic surfactant--the judgment of OSIRIS. The OSIRIS Collaborative Group (open study of infants at high risk of or with respiratory insufficiency--the role of surfactant.
    Lancet; 1992 Dec; 340(8832):1363-9. PubMed ID: 1360087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing surfactant products.
    Prevost RR
    Clin Pharm; 1991 Dec; 10(12):909, 911. PubMed ID: 1773577
    [No Abstract]   [Full Text] [Related]  

  • 9. Colfosceril palmitate. A review of the therapeutic efficacy and clinical tolerability of a synthetic surfactant preparation (Exosurf Neonatal) in neonatal respiratory distress syndrome.
    Dechant KL; Faulds D
    Drugs; 1991 Nov; 42(5):877-94. PubMed ID: 1723378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of two rescue doses of a synthetic surfactant on mortality rate and survival without bronchopulmonary dysplasia in 700- to 1350-gram infants with respiratory distress syndrome. The American Exosurf Neonatal Study Group I.
    Long W; Thompson T; Sundell H; Schumacher R; Volberg F; Guthrie R
    J Pediatr; 1991 Apr; 118(4 Pt 1):595-605. PubMed ID: 2007938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Use of Exosurf Neonatal, a synthetic surfactant, in the treatment of respiratory distress syndrome in the newborn].
    Mikhel'sonVA ; Grebennikov VA; Belaĭ VA; Everstova TN
    Anesteziol Reanimatol; 1995; (1):4-7. PubMed ID: 7605034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surfactant replacement therapy: issues related to currently available preparations.
    Bose G
    Neonatal Netw; 1992 Jun; 11(4):vii-xii. PubMed ID: 1608367
    [No Abstract]   [Full Text] [Related]  

  • 13. Costs and outcomes associated with colfosceril versus beractant for the treatment of neonatal respiratory distress syndrome.
    Wyble L; Santeiro ML
    Ann Pharmacother; 1997 Jun; 31(6):787-8. PubMed ID: 9184726
    [No Abstract]   [Full Text] [Related]  

  • 14. Respiratory distress syndrome in New Zealand: evidence from the OSIRIS trial of exogenous surfactant (Exosurf).
    Wach R; Darlow B; Bourchier D; Broadbent R; Knight D; Selby R
    N Z Med J; 1994 Jun; 107(980):234-7. PubMed ID: 8208494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Natural and synthetic surfactant in the treatment of neonatal respiratory distress syndrome].
    Bratlid D; Farstad T
    Tidsskr Nor Laegeforen; 1994 Jan; 114(1):33-6. PubMed ID: 8296279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The instillated surfactant in the treatment of sepsis-induced ARDS: case report.
    Imperatore F; Postiglione M; Diurno F; Cirillo F; Liguori G; Pica M
    Intensive Care Med; 1999 Mar; 25(3):330-1. PubMed ID: 10229173
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of the changes in the a/A oxygen ratio after administration of two surfactants for the treatment of neonatal respiratory distress syndrome.
    Bassiouny MR; Remo C; Cherian E
    J Trop Pediatr; 1997 Feb; 43(1):38-41. PubMed ID: 9078827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind 1-year follow-up of 1540 infants with respiratory distress syndrome randomized to rescue treatment with two doses of synthetic surfactant or air in four clinical trials. American and Canadian Exosurf Neonatal Study Groups.
    Courtney SE; Long W; McMillan D; Walter D; Thompson T; Sauve R; Conway B; Bard H
    J Pediatr; 1995 May; 126(5 Pt 2):S43-52. PubMed ID: 7745510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-year follow-up of 89 infants with birth weights of 500 to 749 grams and respiratory distress syndrome randomized to two rescue doses of synthetic surfactant or air placebo. Canadian Exosurf Neonatal Study Group. Canadian Exosurf Neonatal Follow-Up Group.
    Casiro O; Bingham W; MacMurray B; Whitfield M; Saigal S; Vincer M; Long W
    J Pediatr; 1995 May; 126(5 Pt 2):S53-60. PubMed ID: 7745512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colfosceril palmitate (Exosurf)--artificial surfactant for immature lungs.
    Drug Ther Bull; 1991 Jun; 29(12):46. PubMed ID: 1935584
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.